The therapeutic value of cannabinoids in MS: Real or imaginary?

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 339-340

  Killestein, Joep ^a   Polman, Chris ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABIS; PLACEBO; TETRAHYDROCANNABINOL;

BODY MOVEMENT; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FREQUENCY ANALYSIS; HUMAN; LONG TERM CARE; MEDICAL ASSESSMENT; MOOD DISORDER; MULTIPLE SCLEROSIS; OPEN STUDY; PAIN; RISK BENEFIT ANALYSIS; SELF REPORT; SPASTICITY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT DISEASE; VISUAL ANALOG SCALE;

CANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS;

EID: 4344599087     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1064ed     Document Type: Editorial

References (9)

1. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
2. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
3. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
4. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62: 1105-109.
5. Goodin D. Marijuana and multiple sclerosis. Lancet Neurol 2004; 3: 79-80.
6. Metz L, Page S. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet 2003; 362: 1513.
7. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis 10: 417-42.
8. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler GJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 10: 425-33.
9. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 10: 434-41.